MARKETS SPECTATOR: Goldman's choice

Goldman Sachs sees cyclical stocks lagging defensives by unprecedented margins, and recommends an overweight position on sectors leveraged to global growth.

In an equity strategy piece from Goldman Sachs, the firm noted that despite the recent outperformance, cyclical stocks have lagged defensives by unprecedented margins given the overall strength in the market.

"At 14x forward earnings, the average cyclical trades at a 20 per cent discount to the average defensive, a valuation gap that remains extremely wide by historical standards. While we forecast a relatively modest 7 per cent market return this year, we expect stronger returns from a cyclical catch-up,” the broker said in the report.

Against this backdrop, Goldman Sachs is recommending being overweight early-cycle domestics that are leveraged to global growth. In particular, it’s recommending overweights in non-bank financials (SUN, HGG, IAG), materials (ORI, IPL, AMC), transports (AIO, BXB, TOL), diversified resources (BHP) and building materials (FBU, BLD).

Looking ahead, the broker believes that investors will increasingly rotate from high-yield defensive names into stocks that offer a better mix of income plus growth, given the improving economic outlook and stretched defensive valuations.

While staples offer a lower yield when compared to REITS, they are expected to deliver superior dividend growth going forward and remain the firms pick for yield plays.

Elsewhere, Goldman has upgraded the steel sector to neutral and downgraded gold to underweight on the premise that downside risk to US growth has been removed. 

InvestSMART FORUM: Come and meet the team

We're loading up the van and going on tour from April to June, with events on the NSW central & north coast, the QLD mid-north coast and in Perth, Adelaide, Melbourne, Sydney and Canberra. Come and meet the team and take home simple strategies that you can use to build an investment portfolio to weather any storm. Book your spot here.

Want access to our latest research and new buy ideas?

Start a free 15 day trial and gain access to our research, recommendations and market-beating model portfolios.

Sign up for free

Related Articles